DESIRE Study - DAY - Diabetes Awareness & You

We value your opinion. Kindly go through few important questions and share your views on it.

Name

Email ID

Mobile No

City

State

Pin Code

PAN

The above information is correct to best of knowledge & I do hereby give my consent to use the information of this survey for research work in future.

1. What percentage of T2DM patients with high CV risk comes to your clinic practice?

a) <10 %

b) 10 %-30 %

c) 30 %-50 %

d) >50 %

2. In your clinical opinion, how often do you check HbA1C after initiating Pharmacotherapy?

a) Every 3 months

b) Every 4 months

c) Every 6 months

d) Yearly

3. Where do you initiate the FDC of Dapagliflozin +Sitagliptin in the management of T2DM in your clinical practice?

a) Newly Diagnosed T2DM

b) Uncontrolled on Metformin Monotherapy

c) Uncontrolled on either Monotherapy

d) All of the above

4. At which HbA1C, do you start this FDC in your clinical practice?

a) <7.5 %

b) ≥ 7.5 %

c) <9 %

d) All of the above

5. In your clinical practice, what is the primary reason for T2DM patients coming for consultation?

a) Uncontrolled Glycemic Parameters

b) Prevention of CV Outcomes

c) Prevention of Renal Outcomes

d) All of the above

6. In your clinical practice, on an average how much HbA1C reduction do you notice with Dapagliflozin + Sitagliptin combination?

a) ≤ 0.5%

b) 0.5 - ≤1 %

c) > 1-≤ 2 %

d) > 2%

7. In your opinion, to have most of the benefits of Dapagliflozin + Sitagliptin, when should it be ideally started in Management of T2DM?

a) Newly Diagnosed T2DM

b) Uncontrolled on Metformin Monotherapy

c) Uncontrolled on either Monotherapy

d) All of the above

8. What type of patients benefit more from this FDC in your clinical practice?

a) Heart Failure Patients

b) CKD Patients

c) Newly Diagnosed Type 2 Diabetes Patients

d) Poorly Controlled Type 2 Diabetes Patients

e) All of the above

9. As per your clinical experience, what are the advantages of this FDC?

a) Better Glycemic Durability

b) Reduction of CV events in HFrEF

c) Lesser Renal Adverse Outcome

d) Extra-glycemic Benefits

e) All of the above

10. In your clinical practice, do you feel this FDC can address most of the problems in T2DM?

a) Not Likely

b) Likely

c) Very Likely

d) None of the above